Penumbra
PEN • NYSE
Penumbra is a medical - devices company in the healthcare sector trading on NYSE, led by CEO Adam Elsesser, with a market cap of $13.2B.
CEOAdam Elsesser
Next Earnings
Upcoming earnings announcement for Penumbra
Date
Wednesday, April 22, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.09
Revenue Estimate
$371.5M
Earnings History
Past 12 earnings reports for Penumbra
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | $1.18Est: $1.12 | +5.4% | $385.4MEst: $364.7M | +5.7% |  10-K |
| Nov 5, 2025 | Q3 2025 | $0.97Est: $0.91 | +6.6% | $354.7MEst: $340.7M | +4.1% | 10-Q |
| Jul 29, 2025 | Q2 2025 | $0.86Est: $0.82 | +4.9% | $339.5MEst: $327.6M | +3.6% | 10-Q |
| Apr 23, 2025 | Q1 2025 | $0.83Est: $0.67 | +23.9% | $324.1MEst: $315.7M | +2.7% | 10-Q |
| Feb 18, 2025 | Q4 2024 | $0.97Est: $0.89 | +9.0% | $315.5MEst: $311.6M | +1.2% | 10-K |
| Oct 30, 2024 | Q3 2024 | $0.85Est: $0.69 | +23.2% | $301.0MEst: $297.4M | +1.2% | 10-Q |
| Jul 30, 2024 | Q2 2024 | $0.64Est: $0.56 | +14.3% | $299.4MEst: $298.4M | +0.3% | 10-Q |
| May 7, 2024 | Q1 2024 | $0.41Est: $0.38 | +7.9% | $278.7MEst: $274.9M | +1.4% | 10-Q |
| Feb 22, 2024 | Q4 2023 | $0.76Est: $0.70 | +8.6% | $284.7MEst: $286.6M | -0.7% | 10-K |
| Nov 2, 2023 | Q3 2023 | $0.67Est: $0.45 | +48.9% | $270.9MEst: $265.3M | +2.1% | — |
| Aug 1, 2023 | Q2 2023 | $0.43Est: $0.28 | +53.6% | $261.5MEst: $253.2M | +3.3% | 10-Q |
| May 2, 2023 | Q1 2023 | $0.23Est: $0.11 | +109.1% | $241.4MEst: $229.7M | +5.1% | — |